Triple-negative breast cancer (TNBC) showed the highest likelihood of pathological complete response (62.4%), while hormone receptor-positive/HER2-negative tumors had the lowest response probability (18.7%). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.